BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 32197218)

  • 1. Comparison of four next generation sequencing platforms for fusion detection: Oncomine by ThermoFisher, AmpliSeq by illumina, FusionPlex by ArcherDX, and QIAseq by QIAGEN.
    Qu X; Yeung C; Coleman I; Nelson PS; Fang M
    Cancer Genet; 2020 May; 243():11-18. PubMed ID: 32197218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CANTRK: A Canadian Ring Study to Optimize Detection of NTRK Gene Fusions by Next-Generation RNA Sequencing.
    Stockley TL; Lo B; Box A; Corredor AG; DeCoteau J; Desmeules P; Feilotter H; Grafodatskaya D; Greer W; Hawkins C; Huang WY; Izevbaye I; Lépine G; Martins Filho SN; Papadakis AI; Park PC; Riviere JB; Sheffield BS; Spatz A; Spriggs E; Tran-Thanh D; Yip S; Zhang T; Torlakovic E; Tsao MS
    J Mol Diagn; 2023 Mar; 25(3):168-174. PubMed ID: 36586421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of gene fusions using targeted next-generation sequencing: a comparative evaluation.
    Heydt C; Wölwer CB; Velazquez Camacho O; Wagener-Ryczek S; Pappesch R; Siemanowski J; Rehker J; Haller F; Agaimy A; Worm K; Herold T; Pfarr N; Weichert W; Kirchner T; Jung A; Kumbrink J; Goering W; Esposito I; Buettner R; Hillmer AM; Merkelbach-Bruse S
    BMC Med Genomics; 2021 Feb; 14(1):62. PubMed ID: 33639937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel 5' fusion partners of ETV1 and ETV4 in prostate cancer.
    Barros-Silva JD; Paulo P; Bakken AC; Cerveira N; Løvf M; Henrique R; Jerónimo C; Lothe RA; Skotheim RI; Teixeira MR
    Neoplasia; 2013 Jul; 15(7):720-6. PubMed ID: 23814484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Frequency and transcript variant analysis of gene fusions between TMPRSS2 and ETS transcription factor genes in prostate cancer].
    Dai MJ; Chen LL; Zheng YB; Chen W; Tao ZH; Weng ZL; Wu XL; Li CD; Chen ZG; Chen XD; Shi SB
    Zhonghua Yi Xue Za Zhi; 2008 Mar; 88(10):669-73. PubMed ID: 18642766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer.
    Han B; Mehra R; Dhanasekaran SM; Yu J; Menon A; Lonigro RJ; Wang X; Gong Y; Wang L; Shankar S; Laxman B; Shah RB; Varambally S; Palanisamy N; Tomlins SA; Kumar-Sinha C; Chinnaiyan AM
    Cancer Res; 2008 Sep; 68(18):7629-37. PubMed ID: 18794152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer.
    Winnes M; Lissbrant E; Damber JE; Stenman G
    Oncol Rep; 2007 May; 17(5):1033-6. PubMed ID: 17390040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
    Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
    Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-resolution ERG-expression profiling on GeneChip exon 1.0 ST arrays in primary and castration-resistant prostate cancer.
    Smit FP; Salagierski M; Jannink S; Schalken JA
    BJU Int; 2013 May; 111(5):836-42. PubMed ID: 23578236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fusion between TMPRSS2 and ETS family members (ERG, ETV1, ETV4) in prostate cancers from northern China.
    Wang JJ; Liu YX; Wang W; Yan W; Zheng YP; Qiao LD; Liu D; Chen S
    Asian Pac J Cancer Prev; 2012; 13(10):4935-8. PubMed ID: 23244085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. External Validation of
    Kim SW; DO SI; Na K
    Anticancer Res; 2021 Sep; 41(9):4609-4617. PubMed ID: 34475089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer.
    Tomlins SA; Laxman B; Dhanasekaran SM; Helgeson BE; Cao X; Morris DS; Menon A; Jing X; Cao Q; Han B; Yu J; Wang L; Montie JE; Rubin MA; Pienta KJ; Roulston D; Shah RB; Varambally S; Mehra R; Chinnaiyan AM
    Nature; 2007 Aug; 448(7153):595-9. PubMed ID: 17671502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TMPRSS2:ETS fusions and clinicopathologic characteristics of prostate cancer patients from Eastern China.
    Dong J; Xiao L; Sheng L; Xu J; Sun ZQ
    Asian Pac J Cancer Prev; 2014; 15(7):3099-103. PubMed ID: 24815454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating Targeted Next-Generation Sequencing Assays and Reference Materials for NTRK Fusion Detection.
    Bormann Chung C; Lee J; Barritault M; Bringuier PP; Xu Z; Huang WY; Beharry A; Castillo J; Christiansen J; Lin JC; Sheffield BS
    J Mol Diagn; 2022 Jan; 24(1):18-32. PubMed ID: 34656759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two unique novel prostate-specific and androgen-regulated fusion partners of ETV4 in prostate cancer.
    Hermans KG; Bressers AA; van der Korput HA; Dits NF; Jenster G; Trapman J
    Cancer Res; 2008 May; 68(9):3094-8. PubMed ID: 18451133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.
    Laxman B; Tomlins SA; Mehra R; Morris DS; Wang L; Helgeson BE; Shah RB; Rubin MA; Wei JT; Chinnaiyan AM
    Neoplasia; 2006 Oct; 8(10):885-8. PubMed ID: 17059688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen regulation of ETS gene fusion transcripts in prostate cancer.
    Gasi D; Trapman J
    Methods Mol Biol; 2011; 776():335-48. PubMed ID: 21796535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer.
    Helgeson BE; Tomlins SA; Shah N; Laxman B; Cao Q; Prensner JR; Cao X; Singla N; Montie JE; Varambally S; Mehra R; Chinnaiyan AM
    Cancer Res; 2008 Jan; 68(1):73-80. PubMed ID: 18172298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testing NTRK testing: Wet-lab and in silico comparison of RNA-based targeted sequencing assays.
    Pfarr N; Kirchner M; Lehmann U; Leichsenring J; Merkelbach-Bruse S; Glade J; Hummel M; Stögbauer F; Lehmann A; Trautmann M; Kumbrink J; Jung A; Dietmaier W; Endris V; Kazdal D; Evert M; Horst D; Kreipe H; Kirchner T; Wardelmann E; Lassen U; Büttner R; Weichert W; Dietel M; Schirmacher P; Stenzinger A
    Genes Chromosomes Cancer; 2020 Mar; 59(3):178-188. PubMed ID: 31652375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers.
    Rajput AB; Miller MA; De Luca A; Boyd N; Leung S; Hurtado-Coll A; Fazli L; Jones EC; Palmer JB; Gleave ME; Cox ME; Huntsman DG
    J Clin Pathol; 2007 Nov; 60(11):1238-43. PubMed ID: 17259299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.